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CONSPECTUS
Non-viral vectors, typically based on cationic lipids or polymers, are preferred due to safety
concerns with viral vectors. So far, non-viral vectors can proficiently transfect cells in culture, but
obtaining efficient nanomedicines is far from evident. To overcome the hurdles associated with
non-viral vectors is significant for improving delivery efficiency and therapeutic effect of nucleic
acid. The drawbacks include the strong interaction of cationic delivery vehicles with blood
components, uptake by the reticuloendothelial system (RES), toxicity, targeting ability of the
carriers to the cells of interest, and so on. PEGylation is the predominant method used to reduce
the binding of plasma proteins with non-viral vectors and minimize the clearance by RES after
intravenous administration. The nanoparticles that are not rapidly cleared from the circulation
accumulate in the tumors due to the enhanced permeability and retention effect, and the targeting
ligands attached to the distal end of the PEGylated components allow binding to the receptors on
the target cell surface. Neutral or anionic liposomes have been also developed for systemic
delivery of nucleic acids in experimental animal model. Designing and synthesizing novel cationic
lipids and polymers, and binding nucleic acid with peptides, targeting ligands, polymers, or
environmentally sensitive moieties also attract many attentions for resolving the problems
encountered by non-viral vectors. The application of inorganic nanoparticles in nucleic acid
delivery is an emerging field, too.
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Recently, different classes of non-viral vectors appear to be converging and the features of
different classes of non-viral vectors could be combined in one strategy. More hurdles associated
with efficient nucleic acid delivery therefore might be expected to be overcome.
In this account, we will focus on these novel non-viral vectors, which are classified into
multifunctional hybrid nucleic acid vectors, novel membrane/core nanoparticles for nucleic acid
delivery and ultrasound-responsive nucleic acid vectors. The systemic delivery studies are
highlighted. Finally, we bring forward the prospect for nucleic acid delivery. We think a better
understandings of the fate of the nanoparticles inside the cell and of the interactions between the
parts of hybrid particles will lead to a delivery system suitable for clinical use. We also underscore
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the value of sustained release of nucleic acid and presume making vectors targeted to cells with
sustained release in vivo should be an interesting research challenge.
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Introduction
Gene therapy has been regarded as a promising and ultimate cure for many acquired and
inherited life-threatening diseases, such as AIDS, cancer, genetic disorders, etc. The efficacy
of a nucleic acid drug requires that the molecule be delivered to the interior of the target
cell.1 Therefore, to achieve successful gene therapy, development of a proper delivery vector
is a significant factor.
The vectors for gene delivery are usually divided into two categories: viral and non-viral (or
synthetic) vectors. Viruses offer greater efficiency of gene delivery, however, non-viral
vectors are preferred due to safety concerns with the viral vectors.2,3 Synthetic vectors are
typically based on cationic lipids or polymers which can complex with negatively charged
nucleic acids to form particles with a diameter in the order of 100 nm. The complex protects
nucleic acid from degradation by nuclease. Moreover, cellular and local delivery strategies
have to deal with the need for internalization, release, and distribution in the proper
subcellular compartment. In the case of DNA therapy, translocation of the DNA into the
nucleus is necessary. In the case of RNA interference (RNAi), siRNA must be delivered to
the RNA-induced silencing complex (RISC) in the cytoplasm. Systemic delivery strategies
encounter additional hurdles, for example, strong interaction of cationic delivery vehicles
with blood components, uptake by the reticuloendothelial system (RES), kidney filtration,
toxicity and targeting ability of the carriers to the cells of interest.4,5
Extensive efforts have been focused on overcoming these barriers and some strategies have
been reviewed lately.4–14 Modifying the surfaces of the cationic non-virals can minimize
their interaction with blood components, reduce RES uptake, decrease their toxicity and
increase their binding affinity with the target cells. Binding of plasma proteins (also termed
opsonization) is the primary mechanism for RES to recognize the circulating nanoparticles.
Macrophages, such as the Kupffer cells in the liver, recognize the opsonized nanoparticles
via the scavenger receptor. Liver, spleen and bone marrow are the major RES organs for
nanoparticle clearance. PEGylation (i.e. modifying the surface with polyethyleneglycol) is
the predominant method used to reduce the opsonization and aggregation of non-viral
vectors and minimize the clearance by RES, leading to a prolonged circulation lifetime after
intravenous (i.v.) administration.4,5 PEGylated nanoparticles are therefore often referred as
“stealth” nanoparticles. The nanoparticles that are not rapidly cleared from the circulation
will have a chance to encounter the leaky tumor vasculature and accumulate in the tumors,
which is known as the enhanced permeability and retention (EPR) effect.4,5 However, PEG
on the surface can decrease the uptake by target cells and reduce the biological activity.
Therefore, to attach targeting ligand to the distal end of the PEGylated component is
necessary; the ligand is projected beyond the PEG “shield” to allow binding to receptors on
the target cell surface.4 When cationic liposome is used as gene carrier, the application of
neutral helper lipid is helpful for the release of nucleic acid, besides promoting hexagonal
phase formation to enable endosomal escape. Some researchers have developed neutral or
anionic liposomes for systemic delivery of nucleic acids and obtained therapeutic effect in
experimental animal model.6,7 Designing and synthesizing novel cationic lipids and
polymers, and covalently or noncovalently binding gene with peptides, targeting ligands,
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polymers, or environmentally sensitive moieties8–11 also attract many attentions for
resolving the problems encountered by non-viral vectors. The application of inorganic
nanoparticles (for example, metallic nanoparticles, iron oxide, calcium phosphate,
magnesium phosphate, manganese phosphate, double hydroxides, carbon nanotubes, and
quantum dots) in gene delivery is an emerging field, too, because they can be prepared and
surface-functionalized in many different ways.12–14
All these extensive efforts still yield very limited information for an effective gene therapy
in clinic and obtaining efficient nanomedicines from non-viral vectors is far from evident.3
Recently, different classes of non-viral vectors appear to be converging; some novel non-
viral vectors were formulated, combining the features of different classes of non-viral
vectors, and hence, might be of multifunction and multipurpose. Such a strategy may not
only avoid the problems associated with the stability, toxicity and protein binding, but also
facilitate the targeted delivery and release of the nucleic acid from the delivery vehicle
within the cell. In this account, we will focus on these novel non-viral vectors and the
studies where therapeutic effect has been observed in vivo will be highlighted.
Multifunctional Hybrid Gene Vectors
Inorganic particles can easily be prepared and surface-functionalized. They exhibit good
storage stability and are not subject to microbial attack. Some inorganic nanoparticles have
been modified in different ways to develop multifunctional gene delivery systems. Two
recent reviews13,14 discussed the strategy based on magnetic inorganic nanoparticles (such
as Fe3O4, MnO2, and so on) for cancer targeted delivery of nucleic acid and simultaneous
diagnosis via magnetic resonance imaging (MRI). Here we will focus on the multifunctional
gene delivery systems based on silica or gold nanoparticles.
An efficient gene delivery carrier and imaging agent for HeLa and NIH3T3 cells has been
developed based on silica nanotubes (SNT, Figure 1).15 The tube structured SNTs are
endowed with two physically distinct domains: the inner void and the outer surface.
Different functionalization of the inner and outer surfaces of SNT could provide a facile and
effective method to integrate multifunctionality. By covalently conjugating the outer surface
of the SNT with cationic, low molecular weight, branched polyethylenimine (BPEI, MW
1.8K), it could easily load pDNA and transport the cargo into the cells. The inner space of
the SNT was filled with a magnetic-fluorescent nanocomposite (iron oxide nanoparticles and
green fluorescent quantum dots (CdSe/ZnS)). Since the walls of SNTs are transparent to
long wavelength UV and visible light, the two caged materials in the inner void could be
used simultaneously for imaging the cell with internalized SNT by MRI, and for monitoring
intracellular movement of SNT by fluorescence. The success of this dual-modality
nanoconstruct in vitro should be expected to drive further research in vivo.
Combination of two or more chemotherapeutic agents with pharmacodynamically
synergistic or additive effects is effectively used in a number of cancer therapy protocols.16
In most cases, a successful drug/gene combination requires delivery of both agents at the
same population of tumor cells in a coordinated manner. Because pharmacokinetics and
disposition profiles of small-molecule drugs and nucleic acid drugs differ greatly, systems
capable of targeted delivery of drug/gene combinations are urgently needed. Bhattarai et al17
modified mesoporous silica nanoparticles (MSN) with poly(ethylene glycol) (PEG) and
poly(2-(dimethylamino)-ethylmethacrylate) or poly(2-(diethylamino)ethylmethacrylate).
The particles were then loaded with a lysosomotropic agent chloroquine (CQ, which is often
used to enhance transfection of non-viral gene delivery vectors in vitro) and complexed with
plasmid DNA or siRNA. By using this polycation-modified MSN, CQ was delivered
simultaneously with DNA or siRNA in vitro, and a significantly increased transfection and
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silencing activity were observed in B16F10 cells when compared with the case using MSN
not loaded with CQ. Considering the fact that when CQ was used alone in vivo, to achieve
the necessary concentrations for enhancing transfection required toxic doses, this study
hypothesized that co-delivery of CQ with plasmid DNA or siRNA in a single particle might
overcome the need for systemic exposure and eventually allow in vivo use of CQ. However,
the hypothesis has yet to be tested in animal models.
Arg-Gly-Asp peptides (RGD) are ligands for αvβ3 integrin receptors. Direct conjugation of
RGD to DNA/PEI (polyethyleneimine) polyplexes can increase the transfection efficiency in
vitro18 and in vivo19. However, these targeting approaches are not able to differentiate
between tumors that express high levels of αvβ3 over tumors that express medium level of
αvβ3 (or over cell types that express low amounts of αvβ3).18,19 To solve this problem,
clustered Arg-Gly-Asp peptides were prepared with Au nanoparticles as template.20 By
introducing clustered RGD ligands on the surface of DNA/PEI polyplexes (Figure 2),
improved targeting of the vector towards U87MG tumors with high levels of αvβ3 integrin
expression over HeLa tumors with medium αvβ3 integrin expression was observed in tumor
bearing mice after i.v. administration.21 This is an interesting study which exploits the
enhanced avidity of multivalent binding.
McMahon et al22 synthesized biomimetic high density lipoprotein (HDL) nanoparticles
based upon a gold nanoparticle template (HDL AuNPs) and found that HDL AuNPs could
adsorb antisense cholesterylated DNA and regulate target gene expression in PC-3 cells in
vitro. HDLs are natural phospholipid-rich cholesterol transporters and can deliver adsorbed
cholesterylated nucleic acids to cell types targeted by HDL for gene regulation. Thus, the
HDL AuNP platform can be expected for the targeted in vivo delivery of nucleic acid.
Polymers also played a role in developing multifunctional nucleic acid delivery systems.
Using poly-L-lysine and PEI as templates, Li et al23 combined prodrug enzyme therapy,
siRNA therapy and simultaneous diagnosis by making prodrug enzyme, siRNA, MRI
reporter and optical reporter into a single systemic treatment strategy for the ER/PR/Her2-
neu negative MDA-MB-231 human breast cancer xenograft model. Prodrug enzyme
therapy, where a drug-activating enzyme delivered to the tumor converts a nontoxic prodrug
to a cytotoxic drug, is being actively investigated to minimize normal tissue damage. The
prodrug enzyme in this report is bacterial cytosine deaminase (bCD) that converts the
nontoxic prodrug 5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU), and the siRNA
mediates choline kinase-α (Chk-α), an enzyme significantly up-regulated in aggressive
breast cancer cells. The combination of siRNA and prodrug enzyme could amplify the
selective targeting of cancer cells while minimize normal tissue damage via i.v.
administration. Meanwhile, noninvasive imaging can demonstrate effective tumor delivery
of the siRNA and prodrug enzyme to determine when the prodrug should be administered,
as well as detecting target down-regulation by siRNA and prodrug conversion by the
enzyme. According to this report, in vivo MRI and optical imaging showed efficient
intratumoral nanoplex delivery, and a single dose of the siRNA/prodrug enzyme containing
nanoplex together with the prodrug resulted in a 6-fold increase of tumor doubling time,
suggesting that image-guided combined siRNA and prodrug enzyme treatment should have
significant potential to improve therapeutic efficacy and minimize normal tissue damage.
This nanoplex strategy could be expected to expand to downregulate multi-drug-resistant
pathways or repair enzymes and increase the efficiency of chemo- or radiation therapy in
vivo.
Recently, as alternative strategies to deliver nucleic acids to tumors, a controlled-release
system responding to the unique environments of tissues and external stimuli has been
investigated. Gold nanorods have strong absorption bands in the near-infrared region, and
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the absorbed light energy is then converted into heat by gold nanorods, the so-called
‘photothermal effect’. Because the near-infrared light can penetrate deeply into tissues, the
surface of gold nanorod could be modified with double-stranded DNA for controlled release
(Figure 3).24 When the dsDNA-modified gold nanorods were irradiated by near-infrared
light, single-stranded DNA was released due to thermo-denaturation induced by the
photothermal effect. The amount of released ssDNA was dependent upon the power and
exposure time of light irradiation. Release of ssDNA was also observed in Colon-26 tumors
grown in mice after light irradiation as the dsDNA modified gold nanorods were directly
injected into the tumors.24 Such a controlled-release system of oligonucleotide triggered by
the photothermal effect could expand the applications of gold nanorods that have unique
optical characteristics.24
Lee et al25 fabricated protease-degradable poly-L-lysine (PLL) and siRNA onto gold
nanoparticles (AuNPs), by layer-by-layer fabrication, which is a gentle assembly procedure
based on charge-charge interactions between positively and negatively charged polymers.
The NPs are multilayered, with the outer surface layer being PLL, could deliver siRNA into
tumor cells, and due to the slow degradation of PLL, the incorporated siRNA could be
released gradually and showed extended gene-silencing effects without toxicity. The
strategy is yet to be tested in animal models.
Novel Membrane/Core Nanoparticles for Gene Delivery
The pharmacology of a liposomal formulation of nucleic acid is largely determined by the
extent to which the nucleic acid is encapsulated inside the liposome bilayer. Encapsulated
nucleic acid is protected from nuclease degradation, while those merely associated with the
surface of the liposome is not protected. Encapsulated nucleic acid shares the extended
circulation lifetime and biodistribution of the intact liposome, while those that are surface
associated adopt the pharmacology of naked nucleic acid once they disassociate from the
liposome.
Liposomal encapsulation of small molecule drugs may be achieved by either “passive” or
“active loading”.26 Unlike small molecule drugs, nucleic acids can not cross intact lipid
bilayers, predominantly due to the large size and hydrophilic nature of the nucleic acid.
Therefore, nucleic acids are entrapped within liposomes with conventional passive loading
technologies, such as ethanol drop method (as in SALP),26 reverse-phase evaporation
method, and ethanol dilution method (as in SNALP).26 These methods rely on the
electrostatic interaction between nucleic acid and cationic lipid; the formation of liposomes
and the encapsulation efficiency of nucleic acid are sensitive to changes in the ionic
strength, cationic lipid, and PEG lipid content, and the scalability and reproducibility are not
satisfactory.26
Recently, a viruslike structure with condensed nucleic acid located inside the lipid
membranes was developed.27,28 It was initially prepared by condensing DNA with
protamine into a compact complex, followed by coating with cationic liposome to obtain
LPD (liposome-polycation-DNA) nanoparticles. The compact complex formed by DNA and
protamine constitutes the core of LPD. Compared with cationic liposome/DNA complex,
LPD offers better protection of plasmid DNA against enzymatic digestion and gives a higher
level of gene expression in mice via intravenous administration. The formulation was also
modified for selectively delivering siRNA to receptor positive tumor cells in vitro and in
vivo (Figures 4 and 5). siRNA was mixed with a carrier DNA, calf thymus DNA, before
complexing with protamine, and PEG conjugated lipids were post-inserted into the outer
lipid membrane to further stabilize the formulation. A targeting ligand (anisamide, a sigma-1
receptor ligand) was conjugated to the distal end of PEG for targeting sigma receptor
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expressing tumor cells.29–33 The PEG on the LPD surface was arranged in a brush mode and
thus, prevented serum opsonization and improved the chance to reach the tumor via EPR
effect. The targeting ligand increased the delivery efficiency and tissue specificity.34
Moreover, by adjusting the ratio of protamine to siRNA and calf-thymus DNA, the core
could be coated with anionic liposomes (formed by DOPA, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine, and cholesterol) to form LPD-II.35 Both LPD and LPD-II can
systemically deliver doxorubicin (Dox) and siRNA to multiple drug resistance (MDR)
tumors simultaneously. Although the same amount of siRNA and Dox delivered by targeted
LPD and LPD-II showed similar levels of apoptosis induction and therapeutic efficacy in
NCI/ADR tumors, LPD-II showed a lower toxicity profile, which might suggest a larger
therapeutic window and potential clinical application for cancer therapy.35
Metallic ions (such as Ca2+ and Mg2+) were also used to mediate and optimize lipoplex
formation. Mozafari et al36,37 once constructed a non-viral and non-cationic gene transfer
vector by incorporating plasmid DNA to the liposomes formed by DPPC
(dipalmitoylphosphatidylcholine)/DCP(dicetylphosphate)/CHOL(cholesterol) liposomes, by
the electrostatic mediation of Ca2+ ions. It is possible to get a high DNA entrapment
capacity and high transfection efficiency in CHO-K1 and 16HBE14o- cells using the anionic
nanolipoplex, but two or three aggregated/semi-fused vesicles were observed as a result of
their complexation with DNA mediated by Ca2+. To avoid this drawback and still employ
the affinity of calcium to the phosphate groups in nucleic acids, novel membrane/core
nanoparticles for siRNA delivery was developed lately. 38 In this strategy, the core of LPD
is replaced with the acid-sensitive nano-sized calcium phosphate (CaP), prepared by using
water-in-oil microemulsions in which siRNA was entrapped. The CaP core was then coated
with DOTAP (1,2-dioleoyl-3-trimethylammonium-propane chloride salt)/cholesterol
liposome membrane (Figure 6). The resulting new formulation is called liposome/calcium/
phosphate, or LCP. The LCP nanoparticles were further modified by post-insertion of PEG
with or without anisamide. The targeted LCP nanoparticles silenced about 70% and 50% of
luciferase activity for H460 cells in culture and those grown in a xenograft model,
respectively. Since CaP rapidly dissolves in the acidic pH, endocytosed CaP should be
deassemble in the endosomes and release its cargo into the cytoplasm. Furthermore, calcium
phosphate is an inorganic component of the biological hard tissues, i.e., bone, teeth, and
tendons, where it exists as carbonated hydroxyapatite. Therefore, the replacement of
DNA(or siRNA)-protamine complex by calcium phosphate/DNA (or siRNA) complex may
also decrease the immunotoxicity. Although calcium phosphates is a well used non-viral
vector for in vitro transfection, their rapid aggregation hinders the application in
vivo.13,39–43 Poly(ethylene glycol)-block-poly(methacrylic acid) was once used to stabilize
CaP crystals, but only the in vitro gene silencing-efficacy was observed.44 Therefore,
wrapping the CaP core with a PEGylated lipid membrane not only stabilizes the core, but
also promises a potential application of CaP for clinical trial.
PEI was also used to condense nucleic acid, followed by modification with liposomes.45,46
Although a decreased toxicity and enhanced biological activity were shown if compared
with the case using nonlipidated PEI, the toxicity of PEI should be still the hurdle for its
application in vivo.
Ultrasound-responsive Gene Vectors
Low-intensity ultrasound in combination with microbubbles has recently acquired much
attention as a safe method of gene delivery. Ultrasound shows tissue-permeabilizing effect.
Ultrasound-triggered delivery allows the control of the deposition of the drug from outside
the patient’s body using suitable force fields.47,48 It is non-invasive and site-specific, and
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could make it possible to destroy tumor cells after systemic delivery, while leave
nontargeted organs unaffected.
In ultrasound-triggered drug delivery, tissue-permeabilizing effect can be potentiated using
ultrasound contrast agents, gas-filled microbubbles.49–51 The use of microbubbles as gene
vectors is based on the hypothesis that destruction of DNA-loaded microbubbles by a
focused ultrasound beam during their microvascular transit through the target area will result
in localized transduction upon disruption of the microbubble shell while sparing non-
targeted areas. However, the therapeutic effect of ultrasound-targeted microbubble
destruction (UTMD) is relative to the size, stability, and targeting function of microbubbles.
Recently, some groups improved the properties of DNA binding microbubbles by using
lipid-stabilized microbubbles. UTMD has been used to deliver genes to cells in vitro and in
vivo, to treat diabetes50, cardiovascular disease,51 and carcinoma 52,53 in experimental
animal models. Negishi et al 54 combined polyethyleneglyco-modified bubble liposomes
and ultrasound exposure and developed a safe and efficient gene delivery system for skeletal
muscle via intraperitoneal administration. More recently, Un et al 55 targeted the bubble
lipoplexes with mannose and developed a DNA vaccination for metastatic and relapsed
melanoma, by transfection of pUb-M, coexpressing ubiquitylated gp100 and TRP-2 (Figure
7). They reported that the vaccine effects against melanoma were sustained for at least 100
days after i.v. administration.
Besides ultrasound-mediated delivery, magnetic targeting delivery could be used for drug
targeting. However, there are fundamental limitations to the use of magnetic drug targeting.
Sufficient magnetic force must be exerted on the nanomagnetic carriers at the target site
before they are cleared from circulation.56,57 Thus, magnetic nanoparticles are usually
entrapped in gene vectors for imaging the delivery of nucleic acid,13–15, 23 as discussed
above. Recently, Vlaskou et al58 generated nucleic acid carriers that combined
responsiveness to both ultrasound and magnetic fields, i.e., magnetic and acoustically active
lipospheres (MAALs). The lipospheres were obtained upon shaking a mixture of soybean
oil, a cationic lipid, magnetic nanoparticles (iron oxide nanoparticles), a nucleic acid, and
aqueous buffer in a perfluoropropane atmosphere in a sealed vial. Although the combined
application of magnetic field and ultrasound had no synergistic effect in terms of liposphere
capture in the lungs, a synergistic effect of magnetic field and ultrasound was observed in
site-specific plasmid deposition in a dorsal skinfold chamber model in mice after injection
into the carotids. This study may indicate that gene delivery mediated by ultrasound
irradiation could be improved if effective means of accumulating and retaining ultrasound
microbubbles at the target sites are available.
It seems that gene therapy using microbubbles as vectors and ultrasound to direct local
transfer of genes to the target site is minimally invasive and is, in theory, easily adapted to
serial treatments. It may become a promising strategy that could circumvent limitations of
viral gene delivery systems. However, to make it an effective therapeutic method in clinic
will require further improvements of the formulation as well as the use of more advanced
ultrasound-transducing device. The biocompatible shell to encapsulate the ultrasound
contrast agent is mainly based on lipid compositions that are used for the preparation of
liposomes. Detailed research on screening lipids and optimizing formulation is necessary.
Prospective and Perspective
Employing chemical and biological strategies to prepare multifunctional vectors to
overcome hurdles associated with efficient cellular nucleic acid delivery has proven to be
beneficial. It has provided exciting new nanomedicine-based strategies for gene therapy.
Unfortunately, progress into clinical trials has been slow. There is insufficient knowledge of
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the physicochemical and biological properties during the various phases of the transfection
process. Leal 59 recently reported the development of cationic liposome-siRNA complexes
with a novel cubic phase nanostructure exhibited efficient silencing with low toxicity. This
finding underscores the importance of understanding membrane-mediated interactions
between cationic liposome-siRNA complex nanostructure and cell components in
developing cationic liposome-based gene silencing vectors. Better understandings of the fate
of the nanoparticles inside the cell and of the interactions between the parts of a hybrid
particle will lead to a delivery system suitable for clinical use. In addition, different cell lines
show a different selectivity towards the hydrophilicity of the particle’s surface when it
comes to the uptake of nanoparticles. A thorough research about the interaction between
cells and vectors is necessary. Escaping the rapid uptake of nanoparticles by the
reticuloendothelial system is also a necessary requirement for an efficient tumor uptake of
the encapsulated nucleic acid.
To date, the delivery of siRNA has predominantly utilized agents that were developed for
plasmid DNA delivery. DNA and RNA are different in physicochemical properties, for
example, the size, the affinity of cation, and the stiffness of the strand (resistance to
condensation), etc. Plasmid DNA needs to be transported into the nucleus for gene
expression, while siRNA only needs to be transferred across the plasma membrane to reach
its target in the cytoplasm. The optimal carriers may be different for these two applications
and delivery reagents should be specifically developed for siRNA delivery. In addition,
RNA is relatively unstable. There are only a few reports so far about the sustained delivery
of siRNA.60–62 How to make vectors targeted to cells with sustained release in vivo should
be an interesting research challenge.
Inorganic nanoparticles offer many ways to prepare systems with a defined particle size,
surface functionalization, nucleic acid protection, and biocompatibility. As it is possible to
finetune their nanostructure, for example, by coating them with different layers or by
loading internal nanopores, their use as carriers could be extended beyond the current
applications. Combination of inorganic nanoparticles with other classes of non-viral vectors
should be an interesting and promising research field.
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Schematic illustration depicting preparation of BPEI-SNT/pDNA complex. Figure is
reproduced from reference [15] with permission.
Guo and Huang Page 14














64Cu-labeled RGD nanocluster-modified DNA/PEI polyplexes. Figure is reproduced from
reference [21] with permission.
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Preparation of dsDNA-modified gold nanorods. Figure is reproduced from reference [24]
with permission.
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Illustration of preparation of PEGylated LPD. Figure is reproduced from reference [30] with
permission.
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In vivo luciferase gene silencing effect of different siRNA formulations at the dose of 150
µg/kg (A) and that of the targeted NP at various doses (B). B16F10 tumor bearing mice were
i.v. injected with different siRNA formulations. Data=mean±SD (n=3–8), * indicates p<0.05
compared to the untreated control. Figure is reproduced from reference [29] with
permission.
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The formation process of liposome/calcium/phosphate (LCP) nanoparticles. Figure is
reproduced from reference [38] with permission.
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Cancer vaccine effects against solid tumors by DNA vaccination using Man-PEG2000 bubble
lipoplexes and US exposure. Figure is reproduced from reference [55] with permission.
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